Skip to main content

Table 2 Univariate analysis of RFS and OS in HCC patients with and without liver cirrhosis after hepatectomy

From: Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching

Variables

RFS

OS

Cirrhosis

No cirrhosis

Cirrhosis

No cirrhosis

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Gender, Female

0.6849 (0.525–0.8935)

0.00526**

0.9562 (0.6888–1.327)

0.789

0.9337 (0.7123–1.224)

0.62

1.364 (0.9753–1.906)

0.0697

Age

0.9907 (0.9816–0.9999)

0.0469*

0.9869 (0.9761–0.9978)

0.0187*

0.9924 (0.9822–1.003)

0.151

0.998 (0.9859–1.01)

0.747

Smoking

1.288 (1.061–1.562)

0.0105*

1.148 (0.9065–1.453)

0.253

1.204 (0.9723–1.49)

0.0888

1.004 (0.771–1.307)

0.978

Drinking

1.431 (1.15–1.782)

0.00135**

1.057 (0.8143–1.372)

0.676

1.145 (0.8962–1.463)

0.279

0.8986 (0.6682–1.208)

0.479

Diabetes

1.017 (0.6841–1.513)

0.932

0.9621 (0.6225–1.487)

0.862

1.477 (0.9974–2.187)

0.0516

0.716 (0.4169–1.23)

0.226

HbsAg( +)

1.425 (0.9989–2.033)

0.0507

1.278 (0.9439–1.731)

0.113

1.034 (0.7357–1.455)

0.845

1.235 (0.8809–1.731)

0.221

AFP, > 400 μg/L

1.649 (1.36–1.998)

 < 0.001**

1.378 (1.083–1.754)

0.00918**

1.655 (1.343–2.04)

 < 0.001**

1.533 (1.179–1.994)

0.00142**

ALBI, ≥ − 2.6

1.185 (0.9697–1.448)

0.097

1.434 (1.097–1.875)

0.00841**

1.291 (1.041–1.602)

0.0202

1.853 (1.398–2.457)

 < 0.001**

NLR, > 1.5

1.194 (0.9601–1.486)

0.111

1.155 (0.8508–1.568)

0.355

1.652 (1.281–2.129)

 < 0.001**

1.318 (0.9193–1.889)

0.133

Nonanatomic hepatectomy

1.152 (0.9522–1.393)

0.146

1.159 (0.9156–1.468)

0.22

1.141 (0.9253–1.407)

0.217

0.9993 (0.764–1.307)

0.996

Portal triad clamping time > 20 min

1.137 (0.9116–1.419)

0.254

1.258 (0.9709–1.63)

0.0825

1.32 (1.043–1.67)

0.0208*

1.308 (0.9811–1.743)

0.0673

Intraoperative blood loss > 400 ml

1.6 (1.271–2.015)

< 0.001**

1.27 (0.9418–1.713)

0.117

1.892 (1.489–2.404)

< 0.001**

1.824 (1.353–2.458)

< 0.001**

Intraoperative blood transfusion

1.533 (1.154–2.036)

0.00318**

1.636 (1.185–2.258)

0.00277**

1.807 (1.355–2.41)

< 0.001**

2.097 (1.508–2.916)

< 0.001**

Tumor diameter, > 5 cm

1.986 (1.64–2.405)

< 0.001**

1.489 (1.168–1.898)

0.00129**

2.253 (1.827–2.777)

< 0.001**

2.175 (1.629–2.904)

 < 0.001**

Multiple tumors

1.168 (0.961–1.419)

0.119

1.436 (1.134–1.818)

0.00264**

1.173 (0.948–1.451)

0.142

1.468 (1.128–1.91)

0.00424**

Pathological grading III/IV

1.677 (1.308–2.149)

< 0.001**

1.386 (1.015–1.89)

0.0397*

1.681 (1.266–2.232)

< 0.001**

1.965 (1.338–2.885)

< 0.001**

Satellite lesions, Yes

1.729 (1.384–2.161)

< 0.001**

2.022 (1.527–2.678)

< 0.001**

2.027 (1.603–2.563)

< 0.001**

1.913 (1.409–2.596)

< 0.001**

MVI

1.86 (1.52–2.275)

< 0.001**

2.108 (1.653–2.687)

< 0.001**

1.933 (1.553–2.406)

 < 0.001**

1.937 (1.474–2.546)

< 0.001**

Macrovascular invasion

3.387 (2.645–4.338)

< 0.001**

3.018 (2.13–4.274)

< 0.001**

2.998 (2.323–3.868)

< 0.001**

2.731 (1.886–3.954)

< 0.001**

Lymphatic metastasis

1.783 (0.9207–3.453)

0.0863

2.159 (1.282–3.636)

< 0.001**

1.74 (0.8973–3.375)

0.101

3.313 (1.958–5.603)

< 0.001**

Prophylactic TACE

1.139 (0.9399–1.381)

0.184

1.036 (0.8171–1.314)

0.769

1.217 (0.9869–1.501)

0.0662

1.097 (0.8434–1.427)

0.49

  1. *P < 0.05 **P < 0.01 RFS: recurrence-free survival, OS overall Survival, ALBI albumin-bilirubin score, NLR neutrophil to lymphocyte ratio, MVI microvascular invasion, Prophylactic TACE prophylactic transcatheter arterial chemoembolization
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us